Suppr超能文献

结直肠癌中zeste 2多梳蛋白家族增强子对claudin 23表达的调控

Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer.

作者信息

Maryan Natalia, Statkiewicz Malgorzata, Mikula Michal, Goryca Krzysztof, Paziewska Agnieszka, Strzałkowska Adriana, Dabrowska Michalina, Bujko Mateusz, Ostrowski Jerzy

机构信息

Department of Gastroenterology and Hepatology, Medical Center for Postgraduate Education, Maria Sklodowska‑Curie Memorial Cancer Center and Institute of Oncology, Warsaw 02‑781, Poland.

Department of Genetics, Maria Sklodowska‑Curie Memorial Cancer Center and Institute of Oncology, Warsaw 02‑781, Poland.

出版信息

Mol Med Rep. 2015 Jul;12(1):728-36. doi: 10.3892/mmr.2015.3378. Epub 2015 Feb 19.

Abstract

Altered epigenetic mechanisms, similar to gene mutations, contribute to the pathogenesis and molecular heterogeneity of neoplasms, including colorectal cancer (CRC). Enhancer of zeste 2 (EZH2) is a histone methyltransferase, which is involved in epigenetic gene silencing and is aberrantly expressed in CRC. Therefore, the identification of the genes regulated by EZH2 in CRC is important to improve current understanding of its role in cancer epigenetics. The present study used chromatin immunoprecipitation (ChIP) followed by deep sequencing to assess genome-wide EZH2‑DNA interactions in healthy or CRC mucosa samples. In total, 86.9/61.6 and 92.5/62.6 million tags were sequenced/mapped in healthy and CRC mucosa samples, respectively. The EZH2-binding densities were correlated with transcriptomic datasets and this demonstrated that the claudin-23 (CLDN23) gene, which encodes a component of cell-cell adhesion structures, was occupied by EZH2 and significantly silenced in CRC tissue. The measurement of DNA methylation at the CLDN23 promoter using pyrosequencing excluded the possibility that silencing of this gene in CRC patient samples was a result of DNA hypermethylation. Following treatment of the Colo205 and HT-29 CRC cell lines, with the EZH2 inhibitor, GSK126, the level of histone H3 lysine 27 trimethylation (H3K27me3) was reduced and the mRNA and protein expression levels of CLDN23 were increased. ChIP analysis confirmed that the level of H3K27m3 along the CLDN23 gene was decreased in the GSK126-treated cell lines. Furthermore, ChIP analysis of these samples detected histone H3 lysine 4 trimethylation (H3K4me3) at the CLDN23 promoter, demonstrating that the balance between H3K27me3 and H3K4me3 may underlie the regulation of the expression of CLDN23. The present study demonstrated an epigenetic link between the activity of the EZH2 methyltransferase at the CLDN23 locus and the expression of CLDN23 in CRC tissue.

摘要

与基因突变类似,表观遗传机制的改变也会导致包括结直肠癌(CRC)在内的肿瘤的发病机制和分子异质性。zeste 2增强子(EZH2)是一种组蛋白甲基转移酶,参与表观遗传基因沉默,且在CRC中异常表达。因此,鉴定CRC中受EZH2调控的基因对于加深目前对其在癌症表观遗传学中作用的理解非常重要。本研究采用染色质免疫沉淀(ChIP)结合深度测序技术,评估健康或CRC黏膜样本中全基因组范围内的EZH2-DNA相互作用。在健康和CRC黏膜样本中,分别对8690万/6160万和9250万/6260万个标签进行了测序/定位。EZH2结合密度与转录组数据集相关,这表明编码细胞间粘附结构成分的claudin-23(CLDN23)基因被EZH2占据,并在CRC组织中显著沉默。使用焦磷酸测序法检测CLDN23启动子处的DNA甲基化,排除了CRC患者样本中该基因沉默是DNA高甲基化结果的可能性。用EZH2抑制剂GSK126处理Colo205和HT-29 CRC细胞系后,组蛋白H3赖氨酸27三甲基化(H3K27me3)水平降低,CLDN23的mRNA和蛋白表达水平升高。ChIP分析证实,在GSK126处理的细胞系中,CLDN23基因上H₃K₂₇m₃的水平降低。此外,对这些样本的ChIP分析在CLDN23启动子处检测到组蛋白H3赖氨酸4三甲基化(H3K4me3),表明H3K27me3和H3K4me3之间的平衡可能是CLDN23表达调控的基础。本研究证明了CRC组织中CLDN23基因座处EZH2甲基转移酶活性与CLDN23表达之间的表观遗传联系。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验